Antiplatelet Drugs Market Set for Rapid Growth, to Surpass US$ 2.9 Billion by 2026

The Global Antiplatelet Drugs Market, by Drug Class (Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIB/IIIA Inhibitors, Adenosine Reuptake Inhibitors, and Thromboxane Inhibitors and Phosphodiesterase Inhibitors), by Mode of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Myocardial Infarction, Percutaneous Coronary Interventions, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1.5 billion in 2017 and is projected to exhibit a CAGR of 7.6over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2190

Antiplatelet therapy is considered to be crucial in preventing aberrant platelet activation in pathophysiological conditions such as ischemia, myocardial infarction, and stroke. According to the Indian Journal of Pharm Science 2007 study, antiplatelet drugs reduce the incidence of cardiovascular events by 20-25% in people with established Coronary Artery Disease (CAD) or at high risk of CAD.

Manufactures in the antiplatelet drugs market focus on targeting either surface receptors or enzymes in the platelet in order to protect against unwanted clot formation following initial platelet activation. Sustained development of new antiplatelet therapies is required as the risk for myocardial infarction and stroke, and death remain a persistent problem for individuals suffering from cardiovascular diseases.

Moreover, cost of drugs is also an important factor influencing compliance with treatment of disease and also constitutes an essential part of rational drug prescription. Pharmaceutical industry has several branded formulation of the same drug with large difference in selling price. For instance, in India, most of the drugs are available in brands and these drugs prescribed by clinician can adversely affect the patient’s finance.

In combination therapy the highest price variation (235.6%) was found for aspirin (75 mg) and clopidogrel (75 mg) followed by aspirin (150 mg) and clopidogrel (75 mg) (24.2%). Therefore, there is a great need for the development of antiplatelet drug with low cost and less side effects along with great efficacy.

Key Takeaways of the Antiplatelet Drugs Market:

The global antiplatelet drugs market is expected to witness a CAGR of 7.6% during the forecast period, owing to increasing prevalence of cardiovascular diseases. According to Centers for Disease Control and Prevention, in 2016, there were around 40,000 children born with coronary heart disease in the U.S.

Among mode of administration, the oral segment is expected to generate significant revenue in 2018, owing to increasing number of oral products available in market.

Major players operating in the global antiplatelet drugs market include, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]



Reset Password